MAGNA Stock Overview
Develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Magnasense AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.17 |
| 52 Week High | SEK 1.00 |
| 52 Week Low | SEK 0.051 |
| Beta | 2.81 |
| 1 Month Change | -49.18% |
| 3 Month Change | 88.03% |
| 1 Year Change | -76.00% |
| 3 Year Change | -98.68% |
| 5 Year Change | n/a |
| Change since IPO | -98.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAGNA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.7% | 0.5% | -0.8% |
| 1Y | -76.0% | 2.8% | 5.5% |
Return vs Industry: MAGNA underperformed the Swedish Biotechs industry which returned 2.8% over the past year.
Return vs Market: MAGNA underperformed the Swedish Market which returned 5.5% over the past year.
Price Volatility
| MAGNA volatility | |
|---|---|
| MAGNA Average Weekly Movement | 71.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: MAGNA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MAGNA's weekly volatility has increased from 36% to 72% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 14 | Marco Witteveen | www.magnasense.com |
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs in Sweden and internationally. The company develops a home testing platform for oral health, therapeutic drug monitoring, and infectious diseases. Its product line includes the Veritope technology with intact natalizumab in multiple sclerosis; and the MagniaReader which is utilized in research and veterinary applications.
Magnasense AB Fundamentals Summary
| MAGNA fundamental statistics | |
|---|---|
| Market cap | SEK 10.77m |
| Earnings (TTM) | -SEK 49.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs MAGNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGNA income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 49.63m |
| Earnings | -SEK 49.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -112.4% |
How did MAGNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 14:19 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Magnasense AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.